Resection extent does not affect survival in astrocytoma with EGFR amplification or pTERT mutation

Greater extent of resection does not appear to affect survival outcomes in patients with isocitrate dehydrogenase (IDH) wildtype grade II astrocytoma and either amplification of the gene encoding epidermal growth factor receptor (EGFR) or mutations in the TERT promoter (pTERT), according to researchers in Italy.

Previous studies have shown that patients with IDH wildtype grade II astrocytoma benefit from gross total resection (GTR), noted Dr Francesco Bruno of the University and City of Health and Science Hospital in Turin, Italy. However, the impact of the extent of resection on outcomes in patients with EGFR amplification or pTERT mutations is unknown.